Boston, MA 10/09/2014 (wallstreetpr) – Advaxis, Inc. (NASDAQ:ADXS) disclosed that it has named Oncologist and research scientist, Samir Khleif, to its Board of Directors. He has over two decades of experience in the field of oncology, immunotherapy and tumor immunology.
Ideal Addition
According to a statement issued to the media, the company said that Khleif’s wide experience in both the business of oncology, as well as, science makes him a perfect addition to its board. The company expects to take advantage of his higher level of guidance and standards in its advancement of registrational trials, technology and much more.
Currently, Khleif was the State of Georgia Cancer Center’s Director, Cancer Service Line and Georgia Regents University Cancer Center. He was a former Chief of the National Cancer Institute’s Cancer Vaccine Section. He was part of the Critical Path Initiative for oncology and was FDA Commissioner’s Special Assistant.
Khleif holds a professorship in Molecular Biology, Biochemistry and Medicine besides being a Cancer Scientist in Georgia Research Alliance.
Research Program
Advaxis, Inc. (NASDAQ:ADXS) said that Khleif research in Georgia centered on cancer-induce immune suppression mechanisms understanding. He was using the knowledge gained to develop novel immune vaccines and therapeutics against cancer. The research group headed by him designed, as well as, performed some of the clinical trials for the first cancer vaccine aimed at particular genetic changes in cancer cells.
Khleif was the author of several book chapters and articles on biomarkers process development and tumor immunology. He was also engaged in editing two textbooks on tumor immunology, cancer vaccines and cancer therapeutics.
Management Comments
The company’s President and CEO, Daniel O’Connor, said that Khleif’s thorough knowledge of immunotherapy products would be very useful specifically for its technology of proprietary Lm-LLO cancer immunotherapy.
Advaxis, Inc. (NASDAQ:ADXS) said that it would look to benefit from Khleif’s guidance as it works carefully to advance its Lm-LLO cancer immunotherapies. It believes that the successful completion of the program would create shareholder value.
